Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma

Summary The presence of a serum monoclonal component has been associated with poor outcomes in some lymphomas. However, data in follicular lymphoma (FL) are scarce. We studied 311 FL patients diagnosed at a single institution, for whom information on serum immunofixation electrophoresis (sIFE) at di...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2021-04, Vol.193 (2), p.299-306
Hauptverfasser: Mozas, Pablo, Rivero, Andrea, Rivas‐Delgado, Alfredo, Fabregat, Aleix, Piñeyroa, Juan A., Correa, Juan G., Nadeu, Ferran, Oliver, Aina, Bataller, Alex, Giné, Eva, Delgado, Julio, Villamor, Neus, Cibeira, Maria T., Fernández de Larrea, Carlos, Rosiñol, Laura, Campo, Elías, Aróstegui, Juan I., Bladé, Joan, Magnano, Laura, López‐Guillermo, Armando
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary The presence of a serum monoclonal component has been associated with poor outcomes in some lymphomas. However, data in follicular lymphoma (FL) are scarce. We studied 311 FL patients diagnosed at a single institution, for whom information on serum immunofixation electrophoresis (sIFE) at diagnosis was available. Baseline characteristics and outcomes were compared between patients with a positive (+sIFE) and a negative sIFE (−sIFE). sIFE was positive in 82 patients (26%). Baseline features were comparable between both groups, except for an older age and higher proportion of elevated β2‐microglobulin levels in the +sIFE group. With a median follow‐up of 4.6 years, a +sIFE was associated with a higher risk of early relapse (POD24, 27% vs. 15%, P = 0·02), shorter progression‐free survival (PFS; 42% vs. 52% at 5 years, P = 0·008), and shorter overall survival (OS; 59% vs. 77% at 10 years, P = 0·046). In patients >60 years, a +sIFE was an independent predictor of OS [hazard ratio (HR) = 2·4, 95% confidence interval (CI): 1·2–5·0; P = 0·02]. Approximately one quarter of patients with FL has a +sIFE at diagnosis, which is a predictor of poor outcome. These findings encourage further investigation of its relationship with B‐cell biology and the tumour microenvironment.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17138